{"denoms":[{"counts":[{"groupId":"BG000","value":"200"},{"groupId":"BG001","value":"203"},{"groupId":"BG002","value":"403"}],"units":"Participants"}],"groups":[{"description":"ARM A: Patients receive one of the four chemotherapy regimens\n\nARM IA: Patients receive chemotherapy comprising docetaxel intravenously (IV) over 1 hour and cisplatin IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nARM IIA: Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nARM IIIA: Patients receive cisplatin IV over 1-2 hours on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nARM IVA: Patients receive carboplatin IV over 30 minutes on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Chemotherapy Arm (Arm A)"},{"description":"ARM B: Patients receive bevacizumab in addition to the chemotherapy regimen as in arm A\n\nARM IB: Patients receive bevacizumab IV over 30-90 minutes on day 1 and docetaxel and cisplatin as in Arm IA.\n\nARM IIB: Patients receive bevacizumab as in arm IB and docetaxel and carboplatin as in Arm IIA.\n\nARM IIIB: Patients receive bevacizumab as in Arm IB and cisplatin and fluorouracil as in Arm IIIA.\n\nARM IVB: Patients receive bevacizumab as in Arm IB and carboplatin and fluorouracil as in Arm IVA.","id":"BG001","title":"Chemotherapy+Bevacizumab (Arm B)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"32","upperLimit":"86","value":"58"},{"groupId":"BG001","lowerLimit":"29","upperLimit":"82","value":"58"},{"groupId":"BG002","lowerLimit":"29","upperLimit":"86","value":"58"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"59"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"168"},{"groupId":"BG001","value":"176"},{"groupId":"BG002","value":"344"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"168"},{"groupId":"BG001","value":"179"},{"groupId":"BG002","value":"347"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"39"}],"title":"Black"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"11"}],"title":"Not reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"All randomized patients"}